ALNY vs REGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REGN Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ALNY counters with relative strength in Valuation. Fundamentally, ALNY trades at 15.0x Forward P/E with 19.5% operating margin (+16.7% YoY revenue) versus REGN at 14.9x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, ALNY sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ALNY Revenue | REGN Revenue | ALNY Op. Margin | REGN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $70M | $5.15B | -1087.6% | 49.3% | REGN |
| FY2019 | $220M | $6.56B | -427.5% | 33.7% | REGN |
| FY2020 | $490M | $8.50B | -168.1% | 42.1% | REGN |
| FY2021 | $840M | $16.1B | -83.9% | 55.7% | REGN |
| FY2022 | $1.04B | $12.2B | -75.7% | 38.9% | REGN |
| FY2023 | $1.83B | $13.1B | -15.4% | 30.9% | REGN |
| FY2024 | $2.25B | $14.2B | -7.9% | 28.1% | REGN |
| FY2025 | $3.71B | $14.3B | 13.5% | 24.9% | REGN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ALNY | REGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $20.0B | $97.8B | Larger Scale | REGN |
| Trailing P/E Ratio Valuation | 7.5x | 20.9x | Lower Multiple | ALNY |
| Forward P/E Ratio Valuation | 15.0x | 14.9x | Lower Multiple | REGN |
| Revenue Growth (YoY) Growth | +16.7% | +36.3% | Higher Growth | REGN |
| Operating Margin (TTM) Profitability | 19.5% | 30.4% | Higher Margin | REGN |
| Net Profit Margin Profitability | 52.8% | 28.5% | Higher Margin | ALNY |
| Return on Equity (ROE) Capital Efficiency | 138.1% | 14.9% | Higher ROE | ALNY |
| 52-Week Range Position Momentum | 0% ($147โ$477) | 83% ($592โ$992) | Stronger Trend | REGN |
| Beta / 30D Volatility Risk Regime | 0.55ฮฒ ยท 94% Vol | 0.32ฮฒ ยท 55% Vol | Lower Realized Risk | REGN |
| Unified Institutional Score Composite Signal | 50.9 / 100 (HOLD) | 42.6 / 100 (HOLD) | Higher Composite | ALNY |